Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

RD4-2025: Selective HIV-1 reverse transcriptase inhibitor in vitro

Aug. 9, 1996

GalaGen's Sporidin G enters phase II/III

Aug. 9, 1996

Immtech's r(m)CRP HIV treatment covered under U.S. patent

Aug. 9, 1996

Cel-Sci now holds full rights to HGP-30

Aug. 9, 1996

BioChem Pharma to challenge Epivir patent

Aug. 9, 1996

A-76202: Alpha-glucosidase/sucrase-isomaltase complex inhibitor from Sankyo

Aug. 9, 1996

Emory University files Epivir patent infringement action

Aug. 9, 1996

Study of Epivir's effect on HIV survival and disease progression terminated

Aug. 9, 1996

Emory University issued U.S. patent covering Epivir

Aug. 9, 1996

Vistide available in U.S. as CMV treatment in AIDS patients

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 28, 2025
New drugs with the same old resistance tricks?
BioWorld
According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with...
OS Therapies heading to FDA with positive osteosarcoma data
BioWorld
With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies Inc. anticipates a regulatory filing...
Vilastobart set apart? Xilio phase II combo performs in CRC
BioWorld
“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...